Alumis Secures $175M in Public Offering to Advance Lupus and Psoriasis Treatments
Alumis Inc., a clinical-stage biopharmaceutical company, has announced plans to raise $175.0 million through a public offering of its common stock. The firm specialises in developing targeted therapies for immune-mediated diseases, including treatments for psoriasis, lupus, and thyroid eye disease.
The offering will be managed by Morgan Stanley, Leerink Partners, Cantor Fitzgerald & Co., and Wells Fargo Securities, who are acting as joint book-running managers. Investors can obtain prospectus supplements and related documents from any of these financial institutions.
Alumis has also indicated it may grant underwriters a 30-day option to buy an extra $26.25 million worth of shares. This move follows the company’s shelf registration statement, filed with the US Securities and Exchange Commission (SEC) on August 19, 2025. The company’s drug pipeline includes envudeucitinib, a treatment for moderate-to-severe plaque psoriasis and systemic lupus erythematosus. Other candidates in development are A-005, aimed at neuroinflammatory and neurodegenerative conditions, and lonigutamab, designed for thyroid eye disease.
The public offering will provide Alumis with additional capital to advance its clinical programmes. Details on the final share price and closing date will be confirmed once the underwriting process is complete. Investors can access further information through the participating financial firms or the SEC’s filings.
